Business Context and Reporting Period
This Form 8-K was filed by pSivida Corp. (not Eyepoint, Inc.) on December 19, 2013. The report details the entry into a material definitive agreement to facilitate the sale of common stock.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial metric disclosed is the potential capital raise:
- Maximum Offering Size: Up to $19,166,895 in aggregate offering price.
- Commission Rate: Up to 3.0% of gross proceeds paid to the sales agent.
Material Changes
On December 19, 2013, the Company entered into an At Market Issuance Sales Agreement with MLV & Co. LLC. This agreement authorizes the Company to issue and sell shares of its common stock through MLV, acting as sales agent, via "at the market" offerings as defined in Rule 415 under the Securities Act of 1933.
Guidance, Outlook, and Risks
Management Commentary: The Company retains control over sales parameters, including the number of shares to be issued and any minimum price below which sales may not be made. MLV will use commercially reasonable efforts consistent with normal trading practices.
Unusual Items/Contingencies: The Company agreed to reimburse MLV for certain expenses related to the agreement and provided customary indemnification rights. The agreement is incorporated by reference into the Company's shelf registration statement on Form S-3.
Investor Verification Checklist
- Verify the current market price of pSivida Corp. common stock to assess the potential dilution impact of the $19.2 million offering.
- Review the full text of the At Market Issuance Sales Agreement (Exhibit 10.1) for specific termination clauses or additional covenants.
- Confirm the Company's current cash position and capital needs to understand the urgency of this financing mechanism.
- Check subsequent filings to determine if and when shares were actually sold under this agreement.